Abiraterone is a selective inhibitor of CYP17A1, the enzyme governing androgen biosynthesis in the testes, adrenal glands and prostate tumour tissue, and is administered (as its acetate ester) for metastatic castration-resistant prostate cancer. Its narrow mechanistic target makes accurate impurity and metabolite characterisation a regulatory priority. Simson Pharma's Abiraterone reference standard and impurities support assay and stability-indicating method validation.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Abiraterone Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.